OCERA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • August 14th, 2013 • Ocera Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of ___________ ____, 2013 by and between Ocera Therapeutics, Inc. (f/k/a Tranzyme, Inc.), a Delaware corporation (the “Company”), and _______________ (“Indemnitee”).
OCERA THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANTOcera Therapeutics, Inc. • August 14th, 2013 • Pharmaceutical preparations • California
This Common Stock Purchase Warrant (the “Warrant”) is issued as of October 1, 2012, by Ocera Therapeutics, Inc., a Delaware corporation (the “Company”), to ________________, or its assigns (the “Holder”). This Warrant is one of a series of Warrants being issued in connection with the sale of Convertible Promissory Notes (the “Notes”) being sold pursuant to the terms of that certain Note and Warrant Purchase Agreement dated as of March 30, 2012 among the Company, the Holder and the other Lenders listed on Exhibit I thereto, as amended by that certain Amendment to Note and Warrant Purchase Agreement and Approval of Subsequent Closing, dated as of October 1, 2012 (collectively, the “Purchase Agreement”). Any capitalized terms used, but not defined, herein shall have the meaning therefor set forth in the Notes.
Ocera Therapeutics, Inc.Ocera Therapeutics, Inc. • August 14th, 2013 • Pharmaceutical preparations
The purpose of this letter agreement is to set forth the principal terms of the agreement that we have reached with respect to you serving as the Chief Executive Officer of Ocera Therapeutics, Inc., a Delaware corporation (the "Company") on an interim basis. That agreement is as follows:
OceraOcera Therapeutics, Inc. • August 14th, 2013 • Pharmaceutical preparations
